Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 1997

View Archived Issues

VM-201 preclinical data presented at AHA meeting

Xoma reports phase II results of Neuprex in trauma patients

Potent antineoplastic camptothecin derivative identified

MMP inhibitors in cardiovascular medicine

Fujisawa: HY 1998 highlights

Texas Biotechnology: Q3 1997 highlights

Onyx: Q3 1997 highlights

Synaptic: Q3 and nine-month highlights

Clinical safety and pharmacology of Vasoflux

Na+/H+ exchange inhibitors isolated from Indonesian medicinal plants

Selective collagenase 3 inhibitor shows promise for osteoarthritis

KE-298 suppresses MMP production in RA synoviocytes

First interim phase III safety results reported for OxSODrol

T-614, a new NSAID that appears to act as a lysosomal protease inhibitor

ImClone receives SBIR grant for angiogenesis research

Xoma develops potential new diagnostic tool for severe infections and sepsis

New vascular gene therapy company established with initial focus on VEGF-2

Roche in-licenses promising antiparkinsonian agent

Biomira: Q3 1997 highlights

nNOS inhibitor from Astra effective in animal models of stroke, ALS

Aradigm tests inhalation form of morphine in volunteers

Pfizer describes new PDE IV inhibitor for asthma

Teva: Q3 1997 highlights

Anti-CD45 MAb prolongs islet xenograft survival in diabetic mice

Ribozyme, Chiron initiate product development of RPI-4610

Allergan to market Penederm products in Central and South America

Peptide + ciclosporin combination improves renal allograft survival and function

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...